| T-Cell/Histiocyte-Rich Large B-Cell Lymphoma studied in …STUDIED_INderived16 of 16show fewer |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · condition mapped CURATED_BROADER · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped CURATED_BROADER · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07097363Phase 2 · recruiting Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544265Phase 1 · recruiting SynKIR-310 for Relapsed/Refractory B-NHL · condition mapped ALIAS · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05934448Phase 2 · recruiting Pembro Plus CAR T-cell Therapy in R/R in PMBCL · condition mapped ONTOLOGY_EXACT · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ALIAS · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583149Phase 2 · active not recruiting Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834373Phase 2 · recruiting Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy · condition mapped CURATED_BROADER · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742258Phase 1 · completed Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05202782Phase 2 · active not recruiting Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma · condition mapped CURATED_BROADER · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03704714Phase 1/Phase 2 · suspended Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (14 active) | — | — | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |